There were no statistically significant differences in the CSF BAFF levels between patients with NBD and the other disease controls, including AM (mean ± SD, 2.2 ± 1.4 ng/ml; median, 1.9 ng/ml) and MS (mean ± SD, 2.7 ± 2.6 ng/ml; median, 2.4 ng/ml). This evidence concerns the gene TNFSF13B and myeloid sarcoma.